Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes

被引:51
作者
Noesslinger, T. [1 ,2 ]
Tuechler, H. [2 ]
Germing, U. [3 ]
Sperr, W. R. [4 ]
Krieger, O. [5 ]
Haase, D. [6 ]
Luebbert, M. [7 ]
Stauder, R. [8 ]
Giagounidis, A. [9 ]
Valent, P. [4 ]
Pfeilstoecker, M. [1 ,2 ]
机构
[1] Hanusch Hosp, Med Dept Hematol & Oncol 3, A-1140 Vienna, Austria
[2] Hanusch Hosp, Ludwig Boltzmann Inst Leukemia Res & Hematol, A-1140 Vienna, Austria
[3] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[4] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria
[5] Elisabethinen Hosp, Dept Hematol & Oncol, Linz, Austria
[6] Univ Gottingen, Dept Hematol & Oncol, Gottingen, Germany
[7] Univ Freiburg, Dept Hematol & Oncol, Freiburg, Germany
[8] Innsbruck Med Univ, Dept Hematol & Oncol, Innsbruck, Austria
[9] St Johannes Hosp, Dept Hematol & Oncol, Duisburg, Germany
关键词
age; gender; IPSS; MDS; prognosis; SCORING SYSTEM; CYTOGENETIC ANALYSIS; PREDICTING SURVIVAL; SINGLE-INSTITUTION; REGRESSION-MODELS; CLASSIFICATION; LENALIDOMIDE; PROPOSALS; LEUKEMIA;
D O I
10.1093/annonc/mdp264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients and methods: In all, 897 patients with primary MDS treated with supportive care only were examined in a retrospective multicenter study. A Cox model was developed to determine the prognostic impact of age and gender on survival and to examine their modulating influence on IPSS results. Based on main effects and interactions of these variables, we established an individualized age- and gender-adapted scoring system to improve prognostication in MDS. Results: While the risk of a patient in the IPSS is best represented by the values 0 (low), +1 (intermediate-1), +2 (intermediate-2), and +3 (high), these values were found to vary between -1.9 and +3.5 in the same patients when including age and gender. Whereas in low-risk MDS, male patients were found to have a less favorable survival, a particularly high risk (+3.5) was found in younger (< 66 years) high-risk female patients. Conclusion: The inclusion of age and gender and their respective interactions contribute to improved and individualized prognostication in MDS.
引用
收藏
页码:120 / 125
页数:6
相关论文
共 26 条
[1]  
AUL C, 1992, LEUKEMIA, V6, P52
[2]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) [J].
Germing, U ;
Hildebrandt, B ;
Pfeilstöcker, M ;
Nösslinger, T ;
Valent, P ;
Fonatsch, C ;
Lübbert, M ;
Haase, D ;
Steidl, C ;
Krieger, O ;
Stauder, R ;
Giagounidis, AAN ;
Strupp, C ;
Kündgen, A ;
Mueller, T ;
Haas, R ;
Gattermann, N ;
Aul, C .
LEUKEMIA, 2005, 19 (12) :2223-2231
[5]   Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 [J].
Giagounidis, AAN ;
Germing, U ;
Haase, S ;
Hildebrandt, B ;
Schlegelberger, B ;
Schoch, C ;
Wilkens, L ;
Heinsch, M ;
Willems, H ;
Aivado, M ;
Aul, C .
LEUKEMIA, 2004, 18 (01) :113-119
[6]   Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms [J].
Gore, SD ;
Baylin, S ;
Sugar, E ;
Carraway, H ;
Miller, CB ;
Carducci, M ;
Grever, M ;
Galm, O ;
Dauses, T ;
Karp, JE ;
Rudek, MA ;
Zhao, M ;
Smith, BD ;
Manning, J ;
Jiemjit, A ;
Dover, G ;
Mays, A ;
Zwiebel, J ;
Murgo, A ;
Weng, LJ ;
Herman, JG .
CANCER RESEARCH, 2006, 66 (12) :6361-6369
[7]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088
[8]  
HAASE D, 1995, BLOOD, V86, P2906
[9]   World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997 [J].
Harris, NL ;
Jaffe, ES ;
Diebold, J ;
Flandrin, G ;
Muller-Hermelink, HK ;
Vardiman, J ;
Lister, TA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3835-3849
[10]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481